Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845470 | 0.86 | OPRK1 (0.47) | SMN1; SMN2LMNACYP2D6OPRK1CACNA1F | |
| SCHEMBL12654239 | 0.82 | MMP9 (0.46) | SMN1; SMN2LMNACYP2D6OPRK1TRPA1 | |
| SCHEMBL24174295 | 0.77 | SIGMAR1 (0.69) | SMN1; SMN2CYP2D6OPRK1CACNA1FCHRM2 | |
| SCHEMBL125129 | 0.73 | CYP3A4 (0.52) | LMNACYP2D6SIGMAR1LTA4H | |
| SCHEMBL14469645 | 0.72 | OPRK1 (0.47) | SMN1; SMN2LMNACYP2D6OPRK1CACNA1F | |
| SCHEMBL11818840 | 0.71 | LMNA (0.63) | LMNACYP2D6TRPA1 | |
| SCHEMBL2622208 | 0.71 | CHRM2 (0.59) | SMN1; SMN2LMNACYP2D6OPRK1CACNA1F | |
| Bromide SCHEMBL11038149 | 0.71 | CYP3A4 (0.50) | LMNACYP2D6SIGMAR1LTA4H | |
| SCHEMBL8260622 | 0.71 | CHRM2 (0.59) | SMN1; SMN2LMNACYP2D6OPRK1CACNA1F | |
| SCHEMBL2622209 | 0.71 | CHRM2 (0.59) | SMN1; SMN2LMNACYP2D6OPRK1CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | SMN1; SMN2 1114/4885LMNA 1680/4885CYP2D6 81/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | SMN1; SMN2 1114/4885LMNA 1680/4885CYP2D6 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.